Journal of General Internal Medicine

, Volume 14, Issue 7, pp 446–448

When should we delay highly active antiretroviral therapy?

  • David R. Bangsberg
  • Andrew Moss


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853–60. See comments.PubMedCrossRefGoogle Scholar
  2. 2.
    Centers for Disease Control and Prevention. Update: trends in AIDS incidence—United States, 1996. MMWR. 1997;46:861–7.Google Scholar
  3. 3.
    Centers for Disease Control and Prevention. HIV AIDS Surveillance Report. December 1998. Washington, DC: US Department of Health and Human Services; 1999.Google Scholar
  4. 4.
    Fairfield KM, Libman H, Davis RB, Eisenberg DM, Phillips RS. Delays in protease inhibitor use in clinical practice. J Gen Intern Med. 1999;14:395–401.PubMedCrossRefGoogle Scholar
  5. 5.
    Johnson PA, Lee TH, Cook EF, Rouan GW, Goldman L. Effect of race on the presentation and management of patients with acute chest pain. Ann Intern Med. 1993;118:593–601.PubMedGoogle Scholar
  6. 6.
    Maynard C, Fisher LD, Passamani ER, Pullum T. Blacks in the coronary artery surgery study (CASS): race and clinical decision making. Am J Public Health. 1986;76:1446–8.PubMedGoogle Scholar
  7. 7.
    Todd KH. Pain assessment and ethnicity. Ann Emerg Med. 1996;27:421–3.PubMedCrossRefGoogle Scholar
  8. 8.
    Moore RD, Bone LR, Geller G, Mamon JA, Stokes EJ, Levine DM. Prevalence, detection, and treatment of alcoholism in hospitalized patients. JAMA. 1989;261:403–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Powe NR, Griffiths RI, de Lissovoy G, et al. Access to recombinant erythropoietin by Medicare-entitled dialysis patients in the first year after FDA approval. JAMA. 1992;268:1434–40.PubMedCrossRefGoogle Scholar
  10. 10.
    Diehr P, Yergan J, Chu J, et al. Treatment modality and quality differences for black and white breast-cancer patients treated in community hospitals. Med Care. 1989;27:942–58.PubMedCrossRefGoogle Scholar
  11. 11.
    Moore RD, Stanton D, Gopalan R, Chaisson RE. Racial differences in the use of drug therapy for HIV disease in an urban community. N Engl J Med. 1994;330:763–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Strathdee SA, Palepu A, Cornelisse PG, et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA. 1998;280:547–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Celentano DD, Vlahov D, Cohn S, Shadle VM, Obasanjo O, Moore RD. Self-reported antiretroviral therapy in injection drug users. JAMA. 1998;280:544–6.PubMedCrossRefGoogle Scholar
  14. 14.
    Vanhove GF, Schapiro JM, Winters MA, Merigan TC, Blaschke TF. Patient compliance and drug failure in protease inhibitor monotherapy. JAMA. 1996;276:1955–6. Letter.PubMedCrossRefGoogle Scholar
  15. 15.
    Montaner JS, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy. The Netherlands, Canada and Australia Study. JAMA. 1998;279:930–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Wainberg MA, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA. 1998;279:1977–83.PubMedCrossRefGoogle Scholar
  17. 17.
    Hecht FM, Grant RM, Petropoulos CJ, et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med. 1998;339:307–11.PubMedCrossRefGoogle Scholar
  18. 18.
    Conlon CP, Klenerman P, Edwards A, Larder BA, Phillips RE. Heterosexual transmission of human immunodeficiency virus type 1 variants associated with zidovudine resistance. J Infect Dis. 1994;169:411–5.PubMedGoogle Scholar
  19. 19.
    Imrie A, Beveridge A, Genn W, Vizzard J, Cooper DA. Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine. Sydney Primary HIV Infection Study Group. J Infect Dis. 1997;175:1502–6.PubMedGoogle Scholar
  20. 20.
    Donovan R, Berrey M, Corey L, Mayers D. Prevalence of Protease Inhibitor and Reverse Transcriptase Inhibitor Resistance Mutations in Recent HIV-1 Seroconverters in Seattle. Presented at the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, Ill, 1999.Google Scholar
  21. 21.
    Boden D, Hurley A, Zhang L, et al. Prevalence of HIV-1 drug resistance mutations in newly infected individuals remains stable over a 3 year period. Presented at the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, Ill, 1999.Google Scholar
  22. 22.
    Ziegelstein RC, Bush DE, Fauerbach JA. Depression, adherence behavior, and coronary disease outcomes. Arch Intern Med. 1998;158:808–9. Letter.PubMedCrossRefGoogle Scholar
  23. 23.
    Carney RM, Freedland KE, Eisen SA, Rich MW, Jaffe AS. Major depression and medication adherence in elderly patients with coronary artery disease. Health Psychol. 1995;14:88–90.PubMedCrossRefGoogle Scholar
  24. 24.
    Carney RM, Freedland KE, Eisen SA, Rich MW, Skala JA, Jaffe AS. Adherence to a prophylactic medication regimen in patients with symptomatic versus asymptomatic ischemic heart disease. Behav Med. 1998;24:35–9.PubMedCrossRefGoogle Scholar
  25. 25.
    Mohr DC, Goodkin DE, Likosky W, Gatto N, Baumann KA, Rudick RA. Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. Arch Neurol. 1997;54:531–3.PubMedGoogle Scholar
  26. 26.
    Cochrane GM. Compliance and outcomes in patients with asthma. Drugs. 1996;52:12–9.PubMedGoogle Scholar
  27. 27.
    Everett KD, Brantley PJ, Sletten C, Jones GN, McKnight GT. The relation of stress and depression to interdialytic weight gain in hemodialysis patients. Behav Med. 1995;21:25–30.PubMedCrossRefGoogle Scholar
  28. 28.
    Sensky T, Leger C, Gilmour S. Psychosocial and cognitive factors associated with adherence to dietary and fluid restriction regimens by people on chronic haemodialysis. Psychother Psychosomat. 1996;65:36–42.CrossRefGoogle Scholar
  29. 29.
    Singh N, Squier C, Sivek C, Wagener M, Nguyen MH, Yu VL. Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: prospective assessment with implications for enhancing compliance. AIDS Care. 1996;8:261–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Patterson D, Swindells S, Mohr J, et al. How Much Adherence is Enough? A Prospective Study of Adherence to Protease Inhibitor Therapy Using MEMSCaps. Presented at the 6th Conference on Retrovirus and Opportunistic Infections, Chicago, Ill, 1999.Google Scholar
  31. 31.
    Ferrando SJ, Wall TL, Batki SL, Sorensen JL. Psychiatric morbidity, illicit drug use and adherence to zidovudine (AZT) among injection drug users with HIV disease. Am J Drug Alcohol Abuse. 1996;22:475–87.PubMedGoogle Scholar
  32. 32.
    Pablos-Mendez A, Knirsch CA, Barr RG, Lerner BH, Frieden TR. Nonadherence in tuberculosis treatment: predictors and consequences in New York City. Am J Med. 1997;102:164–70.PubMedCrossRefGoogle Scholar
  33. 33.
    Caminero JA, Pavon JM, Rodriguez de Castro F, et al. Evaluation of a directly observed six months fully intermittent treatment regimen for tuberculosis in patients suspected of poor compliance. Thorax. 1996;51:1130–3.PubMedCrossRefGoogle Scholar
  34. 34.
    Marco A, Cayl JA, Serra M, et al. Predictors of adherence to tuberculosis treatment in a supervised therapy programme for prisoners before and after release. Study Group of Adherence to Tuberculosis Treatment of Prisoners. Eur Respir J. 1998;12:967–71.PubMedCrossRefGoogle Scholar
  35. 35.
    Tulsky J, Pilote L, Hahn J, Charlebois E, Chesney M, Moss AR. Adherence to TB prevention in the homeless. Presented at the American Thoracic Society Meeting, Chicago, Ill, 1999.Google Scholar
  36. 36.
    Freeman RC, Rodriguez GM, French JF. Compliance with AZT treatment regimen of HIV-seropositive injection drug users: a neglected issue. AIDS Educ Prev. 1996;8:58–71.PubMedGoogle Scholar
  37. 37.
    Samet JH, Libman H, Steger KA, et al. Compliance with zidovudine therapy in patients infected with human immunodeficiency virus, type 1: a cross-sectional study in a municipal hospital clinic. Am J Med. 1992;92:495–502.PubMedCrossRefGoogle Scholar
  38. 38.
    Singh N, Berman S, Swindells S, et al. Adherence to antiretroviral therapy in HIV infected patients: impact of demographic, psychosocial, and medical regimen related variables. Presented at the International Disease Society of America annual meeting, Denver, Colo, 1998.Google Scholar
  39. 39.
    Haubrich R, Little S, Dube M, et al. Self-reported treatment adherence and drug/alcohol use are associated with virologic outcomes in CCTG 570: a clinical strategy trial of HIV antiretroviral monitoring. Presented at the 12th World AIDS Conference, Geneva, Switzerland, 1998.Google Scholar
  40. 40.
    Newman RG, Whitehill WB. Double-blind comparison of methadone and placebo maintenance treatments of narcotic addicts in Hong Kong. Lancet. 1979;2:485–8.PubMedCrossRefGoogle Scholar
  41. 41.
    Dole VP, Robinson JW, Orraca J, Towns E, Searcy P, Caine E. Methadone treatment of randomly selected criminal addicts. N Engl J Med. 1969;280:1372–5.PubMedCrossRefGoogle Scholar
  42. 42.
    Mulvaney FD, Alterman AI, Boardman CR, Kampman K. Cocaine abstinence symptomatology and treatment attrition. J Subst Abuse Treat. 1999;16:129–35.PubMedCrossRefGoogle Scholar
  43. 43.
    Maude-Griffin PM, Hohenstein JM, Humfleet GL, Reilly PM, Tusel DJ, Hall SM. Superior efficacy of cognitive-behavioral therapy for urban crack cocaine abusers: main and matching effects. J Consult Clin Psychol. 1998;66:832–7.PubMedCrossRefGoogle Scholar
  44. 44.
    Siqueland L, Crits-Christoph P, Frank A, et al. Predictors of dropout from psychosocial treatment of cocaine dependence. Drug Alcohol Depend. 1998;52:1–13.PubMedCrossRefGoogle Scholar
  45. 45.
    Cantwell B, McBride AJ. Self detoxication by amphetamine dependent patients: a pilot study. Drug Alcohol Depend. 1998;49:157–63.PubMedCrossRefGoogle Scholar
  46. 46.
    Hando J, Topp L, Hall W. Amphetamine-related harms and treatment preferences of regular amphetamine users in Sydney, Australia. Drug Alcohol Depend. 1997;46:105–13.PubMedCrossRefGoogle Scholar
  47. 47.
    Cameron DW H-CM, Kravick S, et al. The advanced HIV Ritonavir Study Group: prolongation of life and prevention of AIDS complications in advanced HIV immunodeficiency with Ritonavir update. Presented at the 11th International Conference of AIDS. Vancouver, Canada, 1996.Google Scholar
  48. 48.
    Bangsberg D, Tulsky JP, Hecht FM, Moss AR. Protease inhibitors in the homeless. JAMA. 1997;278:63–5.PubMedCrossRefGoogle Scholar
  49. 49.
    Gulick R, Mellors J, Havlir D, et al. Treatment with Indinavir (IDV), Zidovudine (ZDV), and Lamivudine (3TC): three-year follow-up. Presented at the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, Ill, 1999.Google Scholar
  50. 50.
    Rosenberg E. Preserving HIV-1 specific T-cell help: will it prevent progression? Presented at the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, Ill. 1999.Google Scholar
  51. 51.
    Autran B. Effects of antiretroviral therapy on immune reconstitution. Presented at the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, Ill, 1999.Google Scholar
  52. 52.
    Gilbert JR, Evans CE, Haynes RB, Tugwell P. Predicting compliance with a regimen of digoxin therapy in family practice. Can Med Assoc J. 1980;123:119–22.PubMedGoogle Scholar

Copyright information

© Society of General Internal Medicine 1999

Authors and Affiliations

  • David R. Bangsberg
    • 1
  • Andrew Moss
    • 2
  1. 1.Epidemiology and Prevention Intervention CenterSan Francisco General Hospital
  2. 2.Department of Epidemiology and BiostatisticsUniversity of CaliforniaSan Francisco

Personalised recommendations